“The difficulty with bargain shopping… is that you may be understandably hesitant to buy stocks wallowing near their 52-week lows. In an effort to separate the rebound candidates from the laggards, it makes sense to start by determining whether the market has overreacted to a company’s bad news.” Today’s article highlights three stocks trading near their 52-week lows that the author views as “fallen angels” primed for rebounds. One example? Biopharmaceutical giant Gilead Sciences, which was impacted in Q1 by a drop in sales of its hepatitis C pill but which, the author states, “has an exceptionally deep pipeline of potential blockbusters”, including an HIV treatment recently approved by the FDA. To read more, CLICK HERE.